Did you mean?
Search Results - Showing 0 - 12 Of 61
_fatima-karzai-md-on-prostate-cancer-treatment-study-results.jpg "Fatima Karzai, MD, of the National Institutes of Health, discusses phase II findings on olaparib and durvalumab in metastatic castration-resistant prostate cancer in an unselected population (Abstract 163).")
⏲ 1 min 75 sec ✓ 13-Feb-2018
_dr-morgan-on-olaparib-for-metastatic-castration-resistant-prostate-cancer.jpg "OncLiveTV")
⏲ 1 minute 38 seconds 👁 466
_olaparib-zytiga-for-metastatic-castrate-resistant-prostate-cancer-124-learn-about-clinical-trials.jpg "Prostate Cancer Research Institute")
⏲ 3 minutes 48 seconds 👁 2.1K
_highlights-from-asco-2019.jpg "Assistant Prof Bishal Gyawali and Monique Biryiana speak at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the highlights from this year's conference. nnAssistant Prof Gyawali discusses several presentations that address topics ranging from racial disparities, accelerated drug approvals and the importance of assessing overall survival in clinical trials. nnThe presentations that he refer to are: nnAffordable Care Act (ACA) Medicaid expansion impact on racial dispariti")
⏲ 23 min 64 sec ✓ 04-Jun-2019
_the-benefits-of-177lu-psma-617-plus-olaparib-for-prostate-cancer.jpg "VJOncology")
⏲ 1 minute 6 seconds 👁 71
_olaparib-and-keytruda-for-advanced-prostate-cancer-124-124-learn-about-clinical-trials.jpg "Prostate Cancer Research Institute")
⏲ 5 minutes 14 seconds 👁 1.6K
_asco-2023-highlights-and-analysis.jpg "Associate Prof Bishal Gyawali discusses several presentations that on topics ranging from adjuvant treatments, neo-adjuvant treatments and supportive care, across a range of cancer types. He concludes by giving his opinion on issues with drug approval. nnThe presentations referred to are:nn1.Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC)n2.Phase III NATALEE trial of riboci")
⏲ 28 min 40 sec ✓ 06-Jun-2023
_parpi-olaparib-for-the-targeted-treatment-of-metastatic-prostate-cancer.jpg "Vall d'Hebron Institute of Oncology - VHIO")
⏲ 1 minute 49 seconds 👁 209
_parp-inhibitors-for-metastatic-hormone-sensitive-prostate-cancer.jpg "VJOncology")
⏲ 3 minutes 47 seconds 👁 112
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.jpg "Dr Neal Shore speaks to Prof Karim Fizazi about the changing landscape of treatments for prostate cancer, discussing immunotherapies, PARP inhibitors and PSMA testing as future targets and treatments.nnDr Fizazi highlights that anti-PD1 treatment (pembrolizumab) may provide benefit for metastatic castration resistant patients following antiandrogen treatment (5 of the 28 patients in the trial had a PSA decline of50%). nnTrials building on immune checkpoint therapies with novel combinations to")
⏲ 8 min 97 sec ✓ 04-Jun-2018
_the-propel-clinical-trial-exploring-olaparib-plus-abiraterone-in-mcrpc.jpg "VJOncology")
⏲ 1 minute 45 seconds 👁 248
_propel-olaparib-plus-abiraterone-as-1l-treatment-for-metastatic-crpc.jpg "VJOncology")
⏲ 3 minutes 7 seconds 👁 372
Related Searches
Search Videos
Recent Searches
_fatima-karzai-md-on-prostate-cancer-treatment-study-results.webp "Fatima Karzai, MD, of the National Institutes of Health, discusses phase II findings on olaparib and durvalumab in metastatic castration-resistant prostate cancer in an unselected population (Abstract 163).")
_dr-morgan-on-olaparib-for-metastatic-castration-resistant-prostate-cancer.webp "OncLiveTV")
_olaparib-zytiga-for-metastatic-castrate-resistant-prostate-cancer-124-learn-about-clinical-trials.webp "Prostate Cancer Research Institute")
_highlights-from-asco-2019.webp "Assistant Prof Bishal Gyawali and Monique Biryiana speak at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the highlights from this year's conference. nnAssistant Prof Gyawali discusses several presentations that address topics ranging from racial disparities, accelerated drug approvals and the importance of assessing overall survival in clinical trials. nnThe presentations that he refer to are: nnAffordable Care Act (ACA) Medicaid expansion impact on racial dispariti")
_the-benefits-of-177lu-psma-617-plus-olaparib-for-prostate-cancer.webp "VJOncology")
_olaparib-and-keytruda-for-advanced-prostate-cancer-124-124-learn-about-clinical-trials.webp "Prostate Cancer Research Institute")
_asco-2023-highlights-and-analysis.webp "Associate Prof Bishal Gyawali discusses several presentations that on topics ranging from adjuvant treatments, neo-adjuvant treatments and supportive care, across a range of cancer types. He concludes by giving his opinion on issues with drug approval. nnThe presentations referred to are:nn1.Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC)n2.Phase III NATALEE trial of riboci")
_parpi-olaparib-for-the-targeted-treatment-of-metastatic-prostate-cancer.webp "Vall d'Hebron Institute of Oncology - VHIO")
_parp-inhibitors-for-metastatic-hormone-sensitive-prostate-cancer.webp "VJOncology")
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.webp "Dr Neal Shore speaks to Prof Karim Fizazi about the changing landscape of treatments for prostate cancer, discussing immunotherapies, PARP inhibitors and PSMA testing as future targets and treatments.nnDr Fizazi highlights that anti-PD1 treatment (pembrolizumab) may provide benefit for metastatic castration resistant patients following antiandrogen treatment (5 of the 28 patients in the trial had a PSA decline of50%). nnTrials building on immune checkpoint therapies with novel combinations to")
_the-propel-clinical-trial-exploring-olaparib-plus-abiraterone-in-mcrpc.webp "VJOncology")
_propel-olaparib-plus-abiraterone-as-1l-treatment-for-metastatic-crpc.webp "VJOncology")
![[+]](/images/menu.gif){kind=small}